CA2472205A1 — Intermediates for preparing glycogen phosphorylase inhibitors
Assigned to Pfizer Products Inc · Expires 2003-07-24 · 23y expired
What this patent protects
The instant invention provides novel processes and intermediates useful in the preparation of certain N-(indole-2-carbonyl)-.beta.-alaninamide compounds, which compounds are glycogen phosphorylase inhibitors useful in the treatment of diseases such as hypercholesterolemia, hyperg…
USPTO Abstract
The instant invention provides novel processes and intermediates useful in the preparation of certain N-(indole-2-carbonyl)-.beta.-alaninamide compounds, which compounds are glycogen phosphorylase inhibitors useful in the treatment of diseases such as hypercholesterolemia, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, diabetes, diabetic cardiomyopathy, infection, tissue ischemia, myocardial ischemia, and in inhibiting tumor growth.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.